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Abstract
Objective: We studied the influence of the methodologic quality of individual trials on the outcome of
a landmark meta-analysis on thrombolytic therapy in acute myocardial infarction. From each study we
extracted the number of patients in both groups who died in hospital or during follow-up. Methodologic
quality was assessed using the Delphi list. We first recalculated pooled odds ratios (ORs) and 95%
confidence intervals (CIs), on the studies found and compared them with the original results of Yusuf
et al. Next we incorporated the results of quality assessment in five different ways in the calculation of
the pooled ORs: a) component analysis; b) visual plot; c) quality score as a threshold score; d) quality
score as a weighting factor; and e) cumulative pooling.
Results and conclusion: No correlation between quality scores and ORs was found. Studies with a
proper description of the different quality components provided an estimate close to the true treatment
effect. No major differences were found between the results of the five different methods of incorporating
the quality scores into the final conclusion.
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Scientific guidelines for reviewing the literature often include assessment of the method-
ologic quality of the trials (20;21). The value of the conclusion of a meta-analysis not only
depends on the quality of the review process itself, but also on the methodologic quality
of the randomized clinical trials (RCTs) included (10). A leading paradigm in empirical
research is that clinical trials that do not meet certain design criteria, such as concealed
randomization and double blinding, will be usually biased in favor of the intervention and
are therefore more likely to produce larger treatment effects (18;19;22;23).
Assessment of the quality of clinical trials by criteria lists provides an estimation of
the possibility of biased results of a trial. One approach in assessing quality is to focus
on components such as randomization and blinding in trial reports (16;18). Furthermore, a
criteria list can provide a quality score as an estimation of the overall methodologic quality
of the design and conduct of the trial (2). The included studies can be ordered hierarchically
according to quality scores, with higher scores indicating studies with a better methodologic
quality (4). Quality scores can be used as a threshold score for inclusion of the article in a
review, as a weighting factor in the statistical analysis (6;12;23), or as the input sequence
in a cumulative meta-analysis (14;15;23). Finally, a visual plot of the effect size against a
quality score can be presented (14;15;23).
Historically, the effectiveness of thrombolytic therapy for acute myocardial infarction
(AMI) was long disputed. Before 1980 intravenous streptokinase (SK) was tested in RCTs,
but the results were not unequivocally in favor of this therapy. Later, intracoronary appli-
cation of SK became in use because of the angiographically documented recanalization of
the occluded coronary artery. SK became licensed for use in AMI after positive results of
a meta-analysis in 1985 of a study by Yusuf et al. (29) and two very large trials (9;11) in
which the benefit of intravenous thrombolysis in AMI was confirmed. However, cumulative
meta-analysis showed (in retrospect) that there already was a clear evidence of the bene-
fit in 1973 (1;7). Yusuf et al. (29) did not carry out a formal quality assessment in their
meta-analysis. They closed their discussion with a comment on the general validity of their
overview because some trials were “undoubtedly less well executed than others.”
We chose the meta-analysis of the study by Yusuf et al. (29) because the results had
great impact on health care. Its results appeared to be valid, because large trials studying the
same intervention (9;11) confirmed their conclusions, and in a study of Egger et al. (8) the
funnelplot derived from the meta-analysis of Yusuf et al. (29) was not skewed. Therefore, this
meta-analysis offered the possibility of determining a kind of gold standard effect estimate
to study the influence of design characteristics on outcome. In the literature, statements
were made about the direction of bias from design characteristics (19;22), but a reference
effect estimate was never used.
In this research, quality will be measured by the Delphi list (26), which has been devel-
oped by expert consensus, thereby providing some validity (27). We set out to investigate
whether and in which way quality can affect the overall conclusions of a meta-analysis. In
this study we used the meta-analysis of Yusuf et al. (29), and the conclusions of the authors
are regarded as the gold standard.
METHODS
Selection of Studies
All full reports presenting mortality data included in the meta-analysis of Yusuf et al. (29)
are included in this study. Where they used an abstract or personal communication, we
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Table 1. The Delphi List for Quality Assessment
Items Answer option
1. Treatment allocation
a. Was a method of randomization performed? Yes/No/Don’t know
b. Was the treatment allocation concealed? Yes/No/Don’t know
2. Were the groups similar at baseline regarding the most important Yes/No/Don’t know
prognostic indicators?
3. Were the eligibility criteria specified? Yes/No/Don’t know
4. Was the outcome assessor blinded? Yes/No/Don’t know
5. Was the care provider blinded? Yes/No/Don’t know
6. Was the patient blinded? Yes/No/Don’t know
7. Were point estimates and measures of variability presented for the Yes/No/Don’t know
primary outcome measures?
8. Did the analysis include an intention-to-treat analysis? Yes/No/Don’t know
required full reports. Therefore, we searched in MEDLINE and EMBASE and consulted
leading cardiologists in the thrombolytic field. Studies only available as abstracts or personal
communications were excluded, because quality assessment could not be performed.
Quality Assessment
For the quality assessment of individual studies, we applied the Delphi list (26). The Delphi
list is a systematically developed criteria list including nine items, measuring three dimen-
sions of quality: internal validity, external validity, and statistical considerations (Table 1).
It is not designed as a composite scale; items can be used as separate components. The
assessment of the studies was performed independently by two epidemiologists and two
cardiologists. The assessors reached a final score during a consensus meeting resulting in an
overall quality score (QS). The QS consists of the number of items satisfied and ranges from
0–9. We studied the relationship between QS and effect size first by analyzing the effects
of the main components of the QS (component analysis). We then studied the relationship
between the overall QS and effect sizes in several ways: visual plot, using QS as threshold
or weight, or as an input sequence in cumulative pooling.
For the component analysis we divided the studies into three categories of random-
ization: method concealed, method appropriate but not concealed, and method unknown.
Concealed randomization implies that a random (unpredictable) assignment sequence is
generated by an independent person not responsible for determining eligibility of the pa-
tients, and this sequence is concealed until allocation occurs. By appropriate we mean that
reports present additional information about a randomization procedure, which is consid-
ered appropriate in being at random and unpredictable in preventing allocation bias. For
blinding we divided the studies into two categories: blinding reported or not reported. Con-
cerning withdrawals, we divided the studies into three categories: a) no withdrawals or a
withdrawal rate not leading to bias; b) withdrawal rate unknown; and c) a withdrawal rate
possibly leading to bias (meaning> 5% dropouts [Dwithdrawal during the intervention
period]> 20% loss to follow-up [Dwithdrawal during follow-up]). These cut-off points
of 5% and 20% were set according to other frequently used criteria lists (5;24). For the
statistical analysis items, we divided the studies into two categories: performance of an
intention-to-treat (ITT) analysis or not.
Data Extraction
For the main outcome measure, we extracted from each report the number of patients in the
treated and control groups who died in hospital or during follow-up, as mentioned in the
report.
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Analysis
We first recalculated pooled ORs and their 95% confidence intervals (CIs) using a Peto
fixed effects model (all our methods are comparable with the method used by Yusuf et al.),
and compared it with the results of Yusuf et al. (29). Also, a funnelplot was made according
to Egger et al. (7) to evaluate possible publication/selection bias of the studies found.
We calculated intraclass correlation coefficient (ICC) between the four different quality
assessors, and a Spearman rank correlation coefficient to evaluate the relationship between
quality and effect estimate. Next, the QS were incorporated in the pooling in the five different
ways mentioned above.
For the component analysis, we chose to perform a sensitivity analysis and refrained
from meta-regression techniques because of the small number of studies included. For the
overall analysis, we first construct a scatterplot of the QS against the individual ORs. We
also made a scatterplot, including the studies we were unable to find or did not include.
These studies all received a QS of 2. To use the QS as a threshold score, we followed a
suggestion by Chalmers et al. (3) and did a restricted analysis on studies receiving a QS
similar or higher than the mean QS. Further, we also used the QS as a weight: we weighted
each individual study estimate by their achieved Delphi QS, thereby deriving more impact
from higher quality studies on the overall pooled results (6). Finally, to achieve cumulative
pooling, we started the pooling with the study with the highest QS and subsequently added
the others, rank-ordered by decreasing QS.
RESULTS
Trials Included
In the original meta-analysis of Yusuf et al. (29), 33 trials were included. Of four studies, two
reports (short-term and long-term results) of the same trial were available (32;33) (39;40)
(45;46) (56;62). For quality assessment, we chose the report in which the method of re-
search was most clearly described (32;40;45;56). We identified 27 of the original 33 refere-
nces (30;31;32;34;35;36;37;38;40;41;42;43;44;45;47;48;49;50;51;52;54;55;56;58;61;63).
The language of most publications was in English, three in German (34;36;55), one in
French (63), and one in Spanish (49). The Spanish report was translated into English to
facilitate quality assessment. Of the original 33 references, two were based on personal
communications: Hugenholtz PG, Serruys PW, Simoons ML, et al. Randomized trial of
intracoronary thrombolysis in acute myocardial infarction. Personal communication 1985;
Theroux P, personal communication to Furberg C. A trial of intracoronary streptokinase in
acute myocardial infarction. We were able to trace one of them (Hugenholtz et al.) as a full
report (60), and this paper was also included.
After detailed reading, 2 of the 28 references did not meet the selection criteria (i.e.,
RCT, full report, presenting mortality data). One appeared to be a case series instead of
an RCT (42). Although the paper used the terms RCT and control group, it reported the
results of a case series (nD 23), later on compared with a control group (nD 11). Another
report focused on the complications of SK treatment based on data derived from an RCT,
but no data about mortality were presented (52). Both studies were excluded from the
analysis.
Of the remaining 26 references, four were abstracts (48;54;58;61). We found two full
reports of the same group of authors, about the same trial (53;59) and included them in
this research. The main characteristics of the remaining 24 trials and their Delphi QS are
presented in Table 2. In our calculations we used the data of the longest follow-up period
found in the reports.
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Figure 1. Funnelplot of the studies concerning intravenous treatment of MI.
Pooled OR
Following the approach of Yusuf et al., we divided the reports into two categories: intra-
venous (SK or urokinase) and intracoronary (SK) treatment. Regarding intravenous treat-
ment, we included 17 of the original 24 references. Our pooled OR was 0.78 (0.67–0.90),
equal to that of Yusuf et al., 0.78 (0.68–0.89).
Regarding intracoronary treatment, we included seven of the nine original references
of Yusuf et al. (29). We calculated an OR of 0.68 (0.48–0.98). Contrary to Yusuf et al., we
found a significant pooled OR, suggesting that intracoronary treatment with SK is beneficial
for patients with AMI. The pooled OR found by Yusuf et al. was only presented in a figure
(OR… 0.8; 95% CI… 0.55–1.1).
To study the relationship between quality of an RCT and outcome, we restricted our-
selves to the studies concerning intravenous treatment, because we reproduced the same
pooled OR as Yusuf et al. did with the studies found. The funnelplot we made of these 17
studies (Figure 1) showed no apparent publication/selection bias.
Quality Assessment
The QS of the Delphi list is presented in Table 2. The mean QS was 5 (maxD 9). The ICC
between the four quality assessors was 0.54. The Spearman rank correlation coefficient of
the QS versus the OR was ¡0.21.
INCORPORATION OF QUALITY
Component Analysis
Of the included 17 studies, nine (30;35;37;38;39;41;43;51;55) mentioned a concealed ran-
domization, in five studies (31;34;44;49;63) the method was appropriate but not concealed,
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Figure 2. Pooled ORs (95% CI) for subgroup of studies according to the individual
components.
and in three (36;53;59) the method of randomization was unknown. Four studies (36;43;51;
59) mentioned a form of blinding, and all four used the term “double blind.” In eight stud-
ies (34;35;36;37;38;40;41;55) no withdrawals or a withdrawal rate not leading to bias
was found, in seven the withdrawal rate was unknown (31;43;44;49;53;59;63), and in
two studies (30;51) a withdrawal rate “possibly leading to bias” was found. In five stud-
ies (37;38;53;59;63) an ITT analysis was performed. In Figure 2 we present the pooled ORs
and 95% CIs for each component in the different categories.
When the randomization method is unknown or when blinding is reported, the pooled
OR greatly differs from the overall average of true effects (the gold standard pooled OR).
Overall, there is a tendency to underestimate the effect in the categories unknown except for
randomization. When the different components (except blinding) are properly described,
the pooled estimate of effect is close to the gold standard OR.
Visual Plot. To get insight into the relationship between overall quality and effect
sizes, we constructed a scatterplot of the QS against the individual ORs. Figure 3A shows the
Delphi QS (vertically) against the effect size (horizontally) of all 17 full reports. Figure 3B
presents the QS and the ORs of all 24 original studies; the studies that we were unable to find
received a QS of 2. Both plots show no correlation between overall quality score and effect.
Threshold Score. We found a mean quality score of 5 and included studies with at
least a QS of 5. The pooled OR was 0.77 (0.65–0.91). Using a threshold of the median score
(medianD 5) or 50% of the maximum available score (4.5), all provide the same results.
Weighting Factor. We weighted each individual study estimate by their achieved
Delphi QS (Table 1). The pooled estimate was 0.78 (0.73–0.83). There is no difference in
pooled OR using quality scores as a threshold or as a weight. The confidence interval here
using this weighted analysis is smaller because all studies received a weight above 1.
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Figure 3. Scatterplot of the QS against the individual ORs, with (A) showing the ORs of the
17 full reports, and (B) showing the ORs of all 24 original studies.
Cumulative Pooling. We started the cumulative pooling with the highest scoring
study, and subsequently added the ones with lower QS. When 100% of the studies is
included, the original pooled estimate of effect (ORD 0.78) is reached. Figure 4 shows the
cumulative pooling. The number of pooled studies in the category of high-quality studies is
small and the confidence intervals are wide. When the best 40% of the studies is included,
the pooled OR becomes significantly lower than 1.0.
DISCUSSION
We found no apparent influence of methodologic quality on the conclusion of a landmark
meta-analysis on thrombolytic therapy. The results were consistent over the five different
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Figure 4. Cumulative odds ratios.
methods of incorporating the quality into a final conclusion. Studies with a proper description
of different quality components seem to provide a good estimate of the overall average of
true treatment effects.
We decided to accept the pooled OR as found by Yusuf et al. (29) as our gold standard,
providing a true treatment effect. The main reason for this is that after 15 years, its results
still hold. An alternative for setting a gold standard would have been to use the results of
the best qualitative studies. As there were only a few of these, we would have introduced
an unreliable gold standard, so in this study the Yusuf pooled OR is an overall average
score. If the leading paradigm (19;20;22;23) in empirical research is true, meaning that
clinical trials with a poor methodologic quality will usually be biased in favor of the inter-
vention, we expected to find a pooled OR of high-quality studies closer to 1, and a pooled
OR of the lower quality studies lower than the average Yusuf OR of 0.78. However, our
research does not confirm this paradigm in empirical research. We must acknowledge that
the number of studies is small and only a few are high-quality studies. The high-powered
studies (i.e., large sample size) were only of low to moderate quality. Thus, our study
is not strong enough to confidently reject the paradigm, and more empirical studies are
needed.
When a reviewer performs a systematic review or meta-analysis and quality assessment
is a part of the review process, two decisions are important. First, the choice of criteria list
should be used as a valid and reliable measuring instrument. A large number of criteria
lists are available (13;18), and we regard the Delphi list as a relatively valid one because
of the way it is developed (27). Second, the reviewer has to decide how quality will be
incorporated into the final conclusion. In the literature five different ways of incorporating
the quality are described (6;12;15;16;23). Overall, our results of incorporating quality into a
final conclusion is consistent, but component analysis on blinding provides a strange result
we cannot explain.
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Unfortunately, our data set was too small to be able to draw firm conclusions or to use
meta-regression techniques for analyzing possible sources of heterogeneity. Because the
studies we used were all published before the rise of empirical evidence of the importance
of some design characteristics, our data set might be biased one way or the other. It is possible
that authors may not have provided information needed to assess the quality, resulting in
a lower quality score. On the other hand, authors probably did not provide information in
order to be regarded as a high-quality study when it is not.
In conclusion, the use of quality scales and checklists is increasingly criticized. Never-
theless, it is also frequently used because it provides insight into the methodologic quality
in a simple manner. Other studies using similar approaches support our view that effect of
quality on outcome is unclear (13;25;27;28). Quality assessment is seen as an important
part of a meta-analysis, but the influence of quality on outcome is still unclear and needs
further research (13;16;17;25;27;28). In this research, the pooled effect estimate is reached
irrespective of the way quality is incorporated into the final conclusion.
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